Recent Updates
Recently added Catalysts
BNTX

BioNTech Announces Pricing of Initial Public Offering

Thursday, October 10, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BioNTech Announces Pricing of Initial Public Offering

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+16%
120-day peak, hindsight
Typical move
4.5%
average across 2 past catalysts
Lead asset
BNT323
Phase 1 · Locally Advanced Breast Cancer

Full Press Release Details

BioNTech Announces Pricing of Initial Public Offering.

Biotech snapshot

Lead asset
BNT323Phase 1
Locally Advanced Breast Cancer →

Catalyst track record

+16%
best trade around BNTX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for BNTX.

See every catalyst's timing & PoA →